The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy - PubMed (original) (raw)
. 2014 Aug 1;210(3):383-91.
doi: 10.1093/infdis/jiu115. Epub 2014 Feb 28.
Yap Boum 2nd 2, Yong Huang 3, Conrad Muzoora 4, Annet Kembabazi 4, Sheri D Weiser 5, John Bennett 6, Huyen Cao 7, Jessica E Haberer 8, Steven G Deeks 5, David R Bangsberg 9, Joseph M McCune 5, Jeffrey N Martin 6, Peter W Hunt 5
Affiliations
- PMID: 24585899
- PMCID: PMC4148610
- DOI: 10.1093/infdis/jiu115
The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy
Helen Byakwaga et al. J Infect Dis. 2014.
Abstract
Background: Human immunodeficiency virus (HIV) infection-induced indoleamine 2,3-dioxygenase-1 (IDO) expression in activated monocytes and dendritic cells catabolizes tryptophan to kynurenine and other downstream catabolites that inhibit T-cell proliferation and interleukin 17 (IL-17) production. The prognostic significance of this pathway in treated HIV disease is unknown.
Methods: We measured systemic IDO activity (calculated as the ratio of plasma levels of kynurenine to tryptophan; hereafter, the "KT ratio") in HIV-infected Ugandans before and during antiretroviral therapy (ART)-mediated viral suppression and its association with the rate of subsequent CD4(+) T-cell count recovery and mortality.
Results: Among 435 participants, a higher pre-ART KT ratio was associated with a higher plasma virus load (P < .001) and lipopolysaccharide level (P = .018), a lower CD4(+) T-cell count (P < .001), and female sex (P = .047). Through month 12 of ART-mediated viral suppression, the plasma KT ratio decreased by approximately 50% (P < .001). After adjustment for pre-ART CD4(+) T-cell count, virus load, age, and sex, a higher month 12 KT ratio predicted a slower rate of subsequent CD4(+) T-cell count recovery (P = .001). Thirty-nine participants died. After adjustment for pre-ART CD4(+) T-cell count, virus load, body mass index, sex, and age, a higher pre-ART and month 6 KT ratio predicted increased mortality (P ≤ .016).
Conclusions: The kynurenine pathway of tryptophan catabolism independently predicts poor CD4(+) T-cell count recovery and increased mortality among HIV-infected Ugandans initiating ART and may be an important target for interventions.
Keywords: HIV; Tryptophan; Uganda; antiretroviral therapy; indoleamine 2,3-dioxygenase-1; kynurenine; mortality.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
Figures
Figure 1.
Factors associated with the plasma ratio of kynurenine to tryptophan (hereafter, the “KT ratio”) before antiretroviral therapy (ART) initiation in human immunodeficiency virus (HIV)–infected Ugandans. The relationships between the pre-ART KT ratio and the CD4+ T-cell count (A), the plasma HIV RNA level (B), sex and pregnancy status (C), CD4+ T-cell activation (D), CD8+ T-cell activation (E), and plasma lipopolysaccharide (LPS) level (LPS, F) were assessed in 435 HIV-infected Ugandans. Between-group comparisons were assessed with Wilcoxon rank sum tests, and Spearman correlation coefficients were used for comparing continuous variables.
Figure 2.
Impact of antiretroviral therapy (ART)–mediated viral suppression on the plasma ratio of kynurenine to tryptophan (hereafter, the “KT ratio”) in human immunodeficiency virus (HIV)–infected Ugandans. Changes in the KT ratio were assessed in HIV-infected Ugandans during the first year of confirmed ART-mediated viral suppression to <400 copies/mL (A). Boxes represent interquartile ranges, and central bars reflect median values. Error bars span the 5th and 95th percentile values. P values reflect changes from baseline levels assessed with linear mixed models. The correlation between the pre-ART KT ratio and the month 12 KT ratio was also assessed (B).
Figure 3.
Relationship between the plasma ratio of kynurenine to tryptophan (hereafter, the “KT ratio”) and mortality among human immunodeficiency virus (HIV)–infected Ugandans initiating antiretroviral therapy (ART). The relationship between the KT ratio measured before ART initiation (A) and at month 6 of ART-mediated viral suppression of <400 copies/mL (B) and subsequent mortality was assessed with Kaplan-Meier methods. The KT ratio at each time point was assessed in tertiles, and P values reflect findings from tests for trend.
Similar articles
- Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy.
Hunt PW, Cao HL, Muzoora C, Ssewanyana I, Bennett J, Emenyonu N, Kembabazi A, Neilands TB, Bangsberg DR, Deeks SG, Martin JN. Hunt PW, et al. AIDS. 2011 Nov 13;25(17):2123-31. doi: 10.1097/QAD.0b013e32834c4ac1. AIDS. 2011. PMID: 21881481 Free PMC article. - Host genetic predictors of the kynurenine pathway of tryptophan catabolism among treated HIV-infected Ugandans.
Lee SA, Mefford JA, Huang Y, Witte JS, Martin JN, Haas DW, Mclaren PJ, Mushiroda T, Kubo M, Byakwaga H, Hunt PW, Kroetz DL. Lee SA, et al. AIDS. 2016 Jul 17;30(11):1807-15. doi: 10.1097/QAD.0000000000001124. AIDS. 2016. PMID: 27088321 Free PMC article. - Reversal of the Kynurenine pathway of tryptophan catabolism may improve depression in ART-treated HIV-infected Ugandans.
Martinez P, Tsai AC, Muzoora C, Kembabazi A, Weiser SD, Huang Y, Haberer JE, Martin JN, Bangsberg DR, Hunt PW. Martinez P, et al. J Acquir Immune Defic Syndr. 2014 Apr 1;65(4):456-62. doi: 10.1097/QAI.0000000000000062. J Acquir Immune Defic Syndr. 2014. PMID: 24220289 Free PMC article. - Clinical Relevance of Kynurenine Pathway in HIV/AIDS: An Immune Checkpoint at the Crossroads of Metabolism and Inflammation.
Routy JP, Mehraj V, Vyboh K, Cao W, Kema I, Jenabian MA. Routy JP, et al. AIDS Rev. 2015 Apr-Jun;17(2):96-106. AIDS Rev. 2015. PMID: 26035167 Review. - Kynurenine Pathway in Respiratory Diseases.
Pamart G, Gosset P, Le Rouzic O, Pichavant M, Poulain-Godefroy O. Pamart G, et al. Int J Tryptophan Res. 2024 Mar 14;17:11786469241232871. doi: 10.1177/11786469241232871. eCollection 2024. Int J Tryptophan Res. 2024. PMID: 38495475 Free PMC article. Review.
Cited by
- Survival Following Diagnosis of HIV-Associated Kaposi Sarcoma Among Adults in East Africa in the "Treat-All" Era.
Byakwaga H, Semeere A, Laker-Oketta M, Busakhala N, Freeman E, Rotich E, Wenger M, Kadama-Makanga P, Kisuya J, Semakadde M, Mwine B, Kasozi C, Mwebesa B, Maurer T, Glidden DV, Wools-Kaloustian K, Kambugu A, Martin J. Byakwaga H, et al. medRxiv [Preprint]. 2024 Aug 28:2024.08.26.24312536. doi: 10.1101/2024.08.26.24312536. medRxiv. 2024. PMID: 39252899 Free PMC article. Preprint. - The significant role of amino acid metabolic reprogramming in cancer.
Liu X, Ren B, Ren J, Gu M, You L, Zhao Y. Liu X, et al. Cell Commun Signal. 2024 Jul 29;22(1):380. doi: 10.1186/s12964-024-01760-1. Cell Commun Signal. 2024. PMID: 39069612 Free PMC article. Review. - Gut microbiome and cardiometabolic comorbidities in people living with HIV.
Trøseid M, Nielsen SD, Vujkovic-Cvijin I. Trøseid M, et al. Microbiome. 2024 Jun 14;12(1):106. doi: 10.1186/s40168-024-01815-y. Microbiome. 2024. PMID: 38877521 Free PMC article. Review. - High-parameter phenotypic characterization reveals a subset of human Th17 cells that preferentially produce IL-17 against M. tuberculosis antigen.
Ogongo P, Tran A, Marzan F, Gingrich D, Krone M, Aweeka F, Lindestam Arlehamn CS, Martin JN, Deeks SG, Hunt PW, Ernst JD. Ogongo P, et al. Front Immunol. 2024 Apr 18;15:1378040. doi: 10.3389/fimmu.2024.1378040. eCollection 2024. Front Immunol. 2024. PMID: 38698866 Free PMC article. - The plasma kynurenine-to-tryptophan ratio as a biomarker of tuberculosis disease in people living with HIV on antiretroviral therapy: an exploratory nested case-control study.
Gatechompol S, Lutter R, Vaz FM, Ubolyam S, Avihingsanon A, Kerr SJ, van Leth F, Cobelens F. Gatechompol S, et al. BMC Infect Dis. 2024 Apr 2;24(1):372. doi: 10.1186/s12879-024-09258-4. BMC Infect Dis. 2024. PMID: 38565993 Free PMC article.
References
- Hunt PW. HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep. 2012;9:139–47. - PubMed
- Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4:762–74. - PubMed
- Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 1991;5:2516–22. - PubMed
- Grant RS, Naif H, Thuruthyil SJ, et al. Induction of indoleamine 2,3-dioxygenase in primary human macrophages by HIV-1. Redox Rep. 2000;5:105–7. - PubMed
- Sardar AM, Reynolds GP. Frontal cortex indoleamine-2,3-dioxygenase activity is increased in HIV-1-associated dementia. Neurosci Lett. 1995;187:9–12. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P30 MH062246/MH/NIMH NIH HHS/United States
- K23MH087228/MH/NIMH NIH HHS/United States
- R21AI078774/AI/NIAID NIH HHS/United States
- R01 MH054907/MH/NIMH NIH HHS/United States
- P01 AI076174/AI/NIAID NIH HHS/United States
- U19 AI96109/AI/NIAID NIH HHS/United States
- U19 AI096109/AI/NIAID NIH HHS/United States
- K23 MH087228/MH/NIMH NIH HHS/United States
- K24MH087227/MH/NIMH NIH HHS/United States
- T32 AA007240/AA/NIAAA NIH HHS/United States
- R01MH054907/MH/NIMH NIH HHS/United States
- P30AI27763/AI/NIAID NIH HHS/United States
- R21 AI078774/AI/NIAID NIH HHS/United States
- D43 CA153717/CA/NCI NIH HHS/United States
- R56AI100765/AI/NIAID NIH HHS/United States
- K24 MH087227/MH/NIMH NIH HHS/United States
- P30 AI027763/AI/NIAID NIH HHS/United States
- R56 AI100765/AI/NIAID NIH HHS/United States
- T32AA007240/AA/NIAAA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials